The FDA has approved Pfizer's BCMAxCD3 bispecific antibody Elrexfio ... The new drug will be a direct competitor to Johnson & Johnson's Tecvayli (teclistamab), another BCMAxCD3 bispecific that ...

FDA updates safety labels for Pfizer's Abrysvo and GSK's Arexvy RSV vaccines, citing increased Guillain-Barré syndrome risk.

Pfizer's management team recently announced sales and earnings expectations for 2025. An investment-bank analyst thinks Pfizer stock can shoot about 37% higher in 2025. Pfizer has raised its ...

Beata Zawrzel / NurPhoto via Getty Images Pfizer on Tuesday affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit guidance in line with analysts' estimates.

Pfizer (PFE) stock is lower in Tuesday's session ... Impact the Stock Market in 2025 President Trump will have little direct impact on the stock market, but his policies, initiatives and posts ...

Pfizer's stock has underperformed, but management's focus on R&D and cost efficiencies should boost margins and free cash flow, supporting a Buy rating. Despite political headwinds, PFE's ...

RFK Jr. is clearly against unnecessary vaccines and opposed the Covid vaccines that Pfizer benefitted greatly from quickly bringing to market back in 2020. The big question is whether the HHS pick ...